ライフサイエンスコーパス: beta1 adrenoceptor

1 adrenoceptor (1000-fold selectivity over the beta1-adrenoceptor).

2 y analogous to, if not as pronounced as, the beta1-adrenoceptor.

3 eta3-adrenoceptor seems similar to the human beta1-adrenoceptor.

4 d to its antagonistic effects on presynaptic beta1-adrenoceptors.

5 ransmission via an inhibition of presynaptic beta1-adrenoceptors.

6 different agonist conformations of the human beta1-adrenoceptor: 1) where classic agonists (catechola

7 saline or prenalterol (0.1 or 1.0 mg/kg), a beta1 adrenoceptor agonist that increases cardiac rate,

8 l significantly increased peak IBa while the beta1-adrenoceptor agonist dobutamine and beta3-adrenoce

9 Bath application of the selective beta1-adrenoceptor agonist xamoterol hemifumarate (10 mi

10 constriction or on activation of alpha1- and beta1-adrenoceptors and miR-212/132 led to repression of

11 a manner similar to those observed at human beta1-adrenoceptors and unlike those seen at beta2-adren

12 ta2- and beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors, and receptors with single-point mut

13 heir therapeutic effects in migraine through beta1 adrenoceptor antagonist actions in the thalamus.

14 The beta1-adrenoceptor antagonist 1-[2-((3-Carbamoyl-4-hydro

15 Pretest infusions of the beta1-adrenoceptor antagonist atenolol into either the h

16 In the presence of the selective beta1-adrenoceptor antagonist betaxolol hydrochloride (3

17 Metoprolol, a specific beta1-adrenoceptor antagonist, also reversibly enhanced

18 re-evaluated LK 204-545 (1), (1) a selective beta1-adrenoceptor antagonist, and discovered it possess

19 ntagonist, but not by CGP 20712A, a specific beta1-adrenoceptor antagonist.

20 Novel selective beta1-adrenoceptor antagonists for concomitant cardiovas

21 (e.g., cimaterol) are potently inhibited by beta1-adrenoceptor antagonists, and 2) a low-affinity se

22 e] are relatively resistant to inhibition by beta1-adrenoceptor antagonists.

23 ockers have poor selectivity for the cardiac beta1-adrenoceptor (AR) over the lung beta2-AR.

24 identified transmembrane region (TM)4 of the beta1-adrenoceptor as key for this low-affinity conforma

25 ice had equivalent anti-LM defenses, whereas beta1-adrenoceptor (beta1AR)(-/-) FVB/NJ mice had lower

26 ed by a cocktail of an alpha1-(prazosin) and beta1-adrenoceptor (betaxolol) blocker but not by a sele

27 ol, 6 mg x kg(-1)) or central nervous system beta1-adrenoceptor blockade (intracerebroventricular met

28 Central nervous system beta1-adrenoceptor blockade (metoprolol) did not reduce

29 Peripheral beta1-adrenoceptor blockade commenced 6 hrs after lethal

30 Peripheral beta1-adrenoceptor blockade offers anti-inflammatory and

31 Peripheral beta1-adrenoceptor blockade through daily intraperitonea

32 ic responses that are primarily dependent on beta1-adrenoceptors but responses to sustained stress ar

33 At the beta1-adrenoceptor, CGP 12177 potently antagonizes agoni

34 Wild-type beta2- and beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors,

35 e low-affinity pharmacology of the secondary beta1-adrenoceptor conformation.

36 ajor role in the generation of the secondary beta1-adrenoceptor conformation.

37 cooperative interactions between 2 distinct beta1-adrenoceptor conformations.

38 propranolol, respectively) and abolished in beta1-adrenoceptors containing TM4 mutations vital for t

39 ned between in vivo and in vitro measures of beta1-adrenoceptor efficacy (R(2)=0.93; P<0.0001).

40 beta1-adrenoceptors exist in at least two active conform

41 The beta1-adrenoceptor exists in two agonist conformations/s

42 +/-)CGP 12177 (BODIPY-TMR-CGP)] at the human beta1-adrenoceptor expressed in Chinese hamster ovary ce

43 -on e hydrochloride (CGP 12177) at the human beta1-adrenoceptor have provided evidence for two bindin

44 uggests that negative cooperativity across a beta1-adrenoceptor homodimer may be responsible for gene

45 dissociation rate were markedly enhanced in beta1-adrenoceptor homodimers constrained by bimolecular

46 ptors, with beta2-adrenoceptors outnumbering beta1-adrenoceptors in a ratio of 2.9 to 1.

47 Others suggested that TM4 has a role in beta1-adrenoceptor oligomerization.

48 e regulates the activity of agonist-occupied beta1-adrenoceptors on a very fast time scale.

49 Likewise, systemic injections of the beta1-adrenoceptor partial agonist xamoterol (3.0 or 10.

50 o determine the key residues involved in the beta1-adrenoceptor secondary conformation.

51 c nitrile afforded 19, a ligand with similar beta1-adrenoceptor selectivity and partial agonism (log

52 -dependent responses were mainly mediated by beta1-adrenoceptor signaling in TTS.

53 ription to confirm the presence of these two beta1-adrenoceptor sites/conformations and to provide st

54 Prolonged beta1-adrenoceptor stimulation suppresses IKs by downreg

55 Structural modeling of the human beta1-adrenoceptor suggested interaction of the side cha

56 es is a hyperfunctional variant of the human beta1-adrenoceptor that carries an arginine at position

57 ion of a single residue (W199D) in the human beta1-adrenoceptor thus abolished this secondary conform

58 ts were observed with cardiomyocyte-specific beta1-adrenoceptor transgenic mice and human heart biops

59 ed this secondary conformation and created a beta1-adrenoceptor with only one high-affinity agonist c

60 by 275-fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or se